Défis pour réduire la mortalité liée à l'hépatite C: améliorer l'accessibilité au traitement et l'observance thérapeutique

Current therapies with pegylated interferon and ribavirin are effective to eradicate the virus C. Improvements in the treatment are foreseen in the near future with combination of the current treatment with antiviral therapies (antiproteases, antipolymerases). Eradication of the virus, when obtained, has a favorable impact on an individual basis. However, to reduce the mortality related to the virus C at a population level, an important point is the accessibility to the therapy. It has been calculated that the impact of better management of hepatitis C to reduce mortality is minimal, due to a poor accessibility to the therapy. To obtain a significant additional reduction of mortality, a better screening, a better access to therapy and a better compliance are crucial.